Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botulinum toxin A (Botox A®) Clear all
Completed Phase 4 Interventional Results available

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414
View directory record Official record
Conditions
Skin Aging
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939
View directory record Official record
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

NCT00168480
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 1, 2026, 10:03 PM EDT
Recruiting Early Phase 1 Interventional

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

NCT07648290
View directory record Official record
Conditions
Overactive Bladder
Interventions
Macrobid® Capsules 100 mg, Standard Medical Care (SMC)
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 1, 2026, 10:03 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

NCT00234507
View directory record Official record
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed No phase listed Observational

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Davis, California • Irvine, California • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

NCT04949399
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 1, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 1, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

NCT02145676
View directory record Official record
Conditions
Muscle Spasticity, Stroke
Interventions
onabotulinumtoxinA, placebo (normal saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 1, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00915525
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956
View directory record Official record
Conditions
Osteoarthritis
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

NCT03861936
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
OnabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 1, 2026, 10:03 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

NCT07756580
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Glendale, Arizona • Newport Beach, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 1Phase 2 Interventional

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

NCT01088230
View directory record Official record
Conditions
Stroke
Interventions
Botox®, saline solution
Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

NCT01753336
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

NCT01945489
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 1, 2026, 10:03 PM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Upper Limb Spasticity

NCT01603602
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
20
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Sling vs Botox for Mixed Incontinence

NCT04171531
View directory record Official record
Conditions
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions
Botox® injection, Mid-urethral sling
Drug · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 1, 2026, 10:03 PM EDT
Completed No phase listed Observational Results available

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

NCT01608672
View directory record Official record
Conditions
Glabellar Lines
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT02610868
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 1, 2026, 10:03 PM EDT